Prothena Corporation stock reports a narrower Q2 loss

Published on 09/28/2026 at 23:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Prothena Corporation stock posted Q2 revenue of USD 1.01 million on August 6, 2026, above USD 0.42 million consensus. Analysts set a USD 24.57 target.

PRTA, IE00B91XRN20, Illustration mit AI erstellt.

Prothena Corporation plc (ISIN IE00B91XRN20) closed at USD 8.29 on Nasdaq on September 25, 2026, down 0.36 percent for the session. The clinical-stage biotechnology company is being assessed against an average analyst target of USD 24.57 after its latest quarterly report.

Q2 revenue topped consensus

Prothena reported second-quarter revenue of USD 1.01 million on August 6, 2026, compared with a consensus estimate of USD 0.42 million, according to MarketBeat. That is a 140.48 percent revenue difference versus the estimate.

The same report showed a loss of USD 0.32 per share, narrower than the expected USD 0.39 loss. The USD 0.07 improvement equals a 17.95 percent variance against consensus, although Prothena remained unprofitable with a reported negative net margin of 80.68 percent.

Analysts see a wide valuation gap

MarketBeat reported on September 18, 2026, that eight research firms carried a Moderate Buy consensus. Five analysts rated Prothena Buy, one rated it Strong Buy, one rated it Hold and one rated it Sell.

The average 12-month price objective was USD 24.57, while the cited share price was USD 8.46. That target stood 190.43 percent above the cited price, highlighting the unusually broad gap between current market valuation and analyst expectations.

Pipeline remains the central asset

Prothena describes itself as a clinical-stage biotechnology company focused on protein dysregulation and therapies for neurodegenerative and rare amyloid diseases, according to its investor-relations site. Its pipeline includes partnered and wholly owned programs spanning Parkinson's disease, amyloidosis and Alzheimer's disease.

For investors, the latest figures create a split picture: the quarterly revenue and loss both beat consensus, while the negative margin shows that clinical development still carries substantial earnings pressure. The share price therefore remains more sensitive to pipeline milestones than to near-term revenue alone.

PRTA stock closed at USD 8.29

PRTA stock closed at USD 8.29 on Nasdaq on September 25, 2026, with a daily change of minus 0.36 percent. Its market capitalization was USD 425.6 million as of September 25, 2026.